Abstract 86P
Background
Immune-related adverse events (irAEs) are common side effects of immune checkpoint inhibitor (ICI) cancer therapy, affecting around 50% of the ICI treated patients. IrAEs may be severe and lead to hospitalization, permanent organ damage or the need for long-term immunosuppressants. Hospital admission is a generally known factor of poor prognosis, especially in older patients. This study aimed to investigate the clinical risk factors and prognostic significance of irAE-related hospitalization in metastatic real-world cancer patients.
Methods
The study population included all patients (n=202) with metastatic cancers treated with ICI inhibitors at the Cancer Center of Kuopio University Hospital between 2015 and 2023. Data were manually extracted from the local electronic patient registry. IrAEs, their management, hospital stays, subsequent therapies, progression-free survival (PFS) and overall survival (OS) were evaluated.
Results
Of the patients with irAEs, 26% (31/116) needed inpatient treatment. Hospitalization was associated with severe (grade III to IV) toxicities (p<0.001). The mOS of patients hospitalized due to an irAE was 12.9 months, while that of outpatients with irAEs was 26.9 months (p=0.006). The mOS was especially poor if hospital stay exceeded 6 days (7.0 months vs. 19.1 months, p=0.015). Systemic glucocorticoid therapy was administered to 90.3% of hospitalized and 35.3% of non-hospitalized patients (p<0.05). At disease progression after an irAE, palliative care instead of active oncological therapies was more often provided for hospitalized patients (35.4% vs. 17.6%, p=0.041). At the initiation of salvage systemic therapy after an irAE, hospitalized patients tended to be in poorer physical condition than outpatients (WHO performance status >2 in 35.7% vs. 14.6% of patients, p=0.089).
Conclusions
Hospital admission due to an irAE appeared to significantly deteriorate the survival of ICI treated metastatic cancer patients. This may be attributed to decreased physical fitness due to long admissions and high-dose, long-term glucocorticoid treatments of severe irAEs. Early rehabilitation and effective tapering of corticosteroid, if possible, should be provided for patients hospitalized due to an irAE.
Legal entity responsible for the study
Aino Rönkä.
Funding
State Research Funding for university-level health research, Kuopio University Hospital, Wellbeing Service Country of North Savo, Cancer foundation of Finland, Cancer Society of North Savo, The Finnish Medical Foundation sr, Paavo Koistinen Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
Resources:
Abstract
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
Resources:
Abstract
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
Resources:
Abstract
36P - Exploring the role of soluble B7-H3 (sB7-H3) as a biomarker to predict the clinical benefit and/or the occurrence of immune related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Luigi Liguori
Session: Poster Display session
Resources:
Abstract
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
Resources:
Abstract
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
Resources:
Abstract
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
Resources:
Abstract
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
Resources:
Abstract
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract